202664-85-5

Basic information

• Product Name: Methyl 4-acetaMido-2-hydroxy-3-(2-hydroxyethyl)benzoate
• Synonyms: Methyl 4-acetaMido-2-hydroxy-3-(2-hydroxyethyl)benzoate;4-(Acetylamino)-2-hydroxy-3-(2-hydroxyethyl)benzoic acid methyl ester
• CAS NO: 202664-85-5
• Molecular Formula: C₁₂H₁₅NO₅
• Molecular Weight: 253.2512
• EINECS: -0
• Mol File: 202664-85-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 483℃
• Flash Point: 246℃
• Appearance: /
• Density: 1.338
• PKA: 9.39±0.40(Predicted)
• CAS DataBase Reference: Methyl 4-acetaMido-2-hydroxy-3-(2-hydroxyethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-acetaMido-2-hydroxy-3-(2-hydroxyethyl)benzoate(202664-85-5)
• EPA Substance Registry System: Methyl 4-acetaMido-2-hydroxy-3-(2-hydroxyethyl)benzoate(202664-85-5)

Safety Data

• Hazardous Substances Data: 202664-85-5(Hazardous Substances Data)

Upstream product

• 110751-41-2 methyl 2-hydroxy-3-allyl-4-acetaminobenzoate 
• 91958-13-3 methyl 2-allyloxy-4-acetylaminobenzoate 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 
• 202664-83-3 4-(acetylamino)-2-hydroxy-3-(2-oxoethyl)benzoic acid methyl ester 

Downstream Products

• 149466-67-1 methyl 4-acetylamino-2,3-dihydrobenzo[b]furan-7-carboxylate 
• 123654-26-2 4-amino-5-chloro-2,3-dihydrobenzo[b]furan-7-carboxylic acid 
• 143878-29-9 4-acetamido-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid methyl ester 
• 182808-04-4 methyl 4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxylate 
• 137211-64-4 4-amino-5-chloro-2,3-dihydro-N-(4-piperidinyl)benzofuran-7-carboxamide 
• 179474-81-8 prucalopride 
• 179474-85-2 prucalopride succinate 

Relevant articles and documents

Synthesis and structure-activity relationship of 3-substituted benzamide, benzo[b]furan-7-carboxamide, 2,3-dihydrobenzo[b]furan-7- carboxamide, and indole-5-carboxamide derivatives as selective serotonin 5- HT4 receptor agonists

The title compounds (6-9) were prepared and evaluated for serotonin 5- HT4 agonistic activity in in vitro tests. Introducing a propyl or allyl group at the 3-position of benzamide caused only a slight enhancement of agonistic activity. Construction of the benzo[b']furan skeleton and 2,3- dihydrobenzo[b]furan skeleton caused a significant enhancement of the activity. 4-Amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2- methylbenzo[b]furan-7-carboxamide (7b) hemifumarate was as potent as cisapride. 4-Amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2,3- dihydro-2-methylbenzo[b]furan-7-carboxamide (8a) hemifumarate, 4-amino-N-[2- (1-azabicyclo [3.3.0]octan-5-yl)ethyl]5-chloro-2,3-dihydro-2- ethylbenzo[b]furan-7-carboxamide (8c) hemifumarate, and 4-amino-N-]2-(1- azabicyclo[3.3.0]octan-5-yl]-5-chloro-2,3-dihydro-2,3-dimethylhenzo[b]furan- 7-carboxamide (8d) hemifumarate were more potent than cisapride. Furthermore, 8a hemifumarate was free from dopamine D1, D2, serotonin 5-HT1, 5-HT2 and muscarine M1, M2 receptor binding activity in the in vitro tests. On the other hand, construction of the indole skeleton caused a remarkable decrease in activity.